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Background: Costs of in vitro fertilisation (IVF) are high, which is partly due to the use of follicle stimulating
hormone (FSH). FSH is usually administered in a standard dose. However, due to differences in ovarian reserve
between women, ovarian response also differs with potential negative consequences on pregnancy rates. A Markov
decision-analytic model showed that FSH dose individualisation according to ovarian reserve is likely to be
cost-effective in women who are eligible for IVF. However, this has never been confirmed in a large randomised
controlled trial (RCT). The aim of the present study is to assess whether an individualised FSH dose regime based
on an ovarian reserve test (ORT) is more cost-effective than a standard dose regime.
Methods/Design: Multicentre RCT in subfertile women indicated for a first IVF or intracytoplasmic sperm injection
cycle, who are aged < 44 years, have a regular menstrual cycle and no major abnormalities at transvaginal
sonography. Women with polycystic ovary syndrome, endocrine or metabolic abnormalities and women
undergoing IVF with oocyte donation, will not be included. Ovarian reserve will be assessed by measuring the
antral follicle count. Women with a predicted poor response or hyperresponse will be randomised for a standard
versus an individualised FSH regime (150 IU/day, 225-450 IU/day and 100 IU/day, respectively). Participants will
undergo a maximum of three stimulation cycles during maximally 18 months. The primary study outcome is the
cumulative ongoing pregnancy rate resulting in live birth achieved within 18 months after randomisation.
Secondary outcomes are parameters for ovarian response, multiple pregnancies, number of cycles needed per live
birth, total IU of FSH per stimulation cycle, and costs. All data will be analysed according to the intention-to-treat
principle. Cost-effectiveness analysis will be performed to assess whether the health and associated economic
benefits of individualised treatment of subfertile women outweigh the additional costs of an ORT.
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Discussion: The results of this study will be integrated into a decision model that compares cost-effectiveness of
the three dose-adjustment strategies to a standard dose strategy. The study outcomes will provide scientific
foundation for national and international guidelines.
Trial registration: NTR2657
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In vitro fertilisation (IVF) is the treatment of last resort
for many subfertile couples and a very costly one, partly
due to the use of expensive drugs, i.e. gonadotrophins,
needed for controlled ovarian hyperstimulation (COH)
[1]. COH is an essential part of IVF which is needed to
obtain a reasonable yield of oocytes which can then be
fertilised in vitro. In clinical practice physicians often
rely on their clinical experience and judgement when
selecting an appropriate starting dose of follicle stimula-
tion hormone (FSH). There is neither international nor
nationwide consensus about COH programmes. Defin-
ing the optimal dose of FSH to retrieve an acceptable
number of oocytes remains complicated. The problem
herewith is that women show marked differences in their
ovarian reserve and, as a consequence, in their ovarian
response to medication [2,3]. Women who respond
poorly to ovarian stimulation have poorer pregnancy
prospects than women with a normal ovarian response
[4]. Frequently, the occurrence of an insufficient re-
sponse will urge the clinician to cancel the cycle which
is obviously very stressful to the couple and may lead to
withdrawal from further treatment. In a subsequent
stimulation cycle higher dosages of FSH are usually
given, although these may also be inadequate, leading to
another cancellation of the cycle or even to hyperre-
sponse with risk of ovarian hyperstimulation syndrome
(OHSS). The result is that the poor responder may go
through a series of treatment cycles with an overall poor
prospect for pregnancy.
On the other end of the spectrum, women with a
hyperresponse to ovarian stimulation are at risk of
increased patient discomfort, cycle cancellation and de-
velopment of OHSS. This condition may lead to severe
illness requiring hospitalisation and intensive care with
thromboembolic phenomena or multiple organ failure
which are potentially life threatening complications.
Mild and moderate forms of OHSS occur in respectively
20–33% and 3–6% of all ovarian stimulation cycles,
while the severe form of the syndrome has been
reported to occur as frequently as 0.1–2% [5].
In view of the tight relationship between hyperre-
sponse and OHSS, prevention of hyperresponse is one
of the key elements in preventing OHSS. Accurate pre-
diction of ovarian response is now possible by using anovarian reserve test (ORT) [6]. Various ORTs are avail-
able, of which basal FSH is the oldest whereas the antral
follicle count (AFC) and serum level of anti-Müllerian
hormone (AMH) have been introduced more recently.
Previous systematic reviews by our group have shown
that both AFC and AMH provide an optimal balance be-
tween sensitivity and specificity, are superior to basal
FSH, and are able to predict ovarian response to COH,
allowing for studies on the value of adjustment of the
FSH dosage based on these parameters [6-10]. It should
be emphasised that our reviews showed that ORTs can
predict ovarian response after COH, but not the occur-
rence of pregnancy after IVF treatment.
Previous research has shown that dose adjustment
after ORTs resulted in a higher rate of normal ovarian
response and significantly higher pregnancy rates [11].
However, this study had several weaknesses. First of all,
the power calculation was not based on the outcome
‘pregnancy’ but on the outcome ‘appropriate response’.
Furthermore, participants with possible extremes in
ovarian response were excluded, FSH dosage was only
fixed until stimulation day 8, and the used algorithm
was complicated and impractical for daily clinical use.
Before definitive conclusions can be drawn about dose
adjustment after ORTs, these results need to be con-
firmed in a large randomised controlled trial (RCT).
Based upon these data, we hypothesize that the use of
an ORT as predictor of ovarian response followed by an
individualised FSH regime, will lead to a reduction in
the occurrence of an inappropriate ovarian response, a
reduction in the amount of cycle cancellations, reduc-
tion in the number of withdrawals from treatment, re-
duction in the occurrence of OHSS, reduction in the
application of cycles with poor prospects for success, im-
provement in overall pregnancy rates and improvement
of overall cost-effectiveness of IVF programs.
Methods
Study design
The OPTIMIST trial is a nationwide multicentre RCT.
The cohort will consist of 1,500 women screened for
ovarian reserve by an AFC prior to IVF or intracytoplas-
mic sperm injection (ICSI) treatment. Two RCTs are
embedded in this cohort. Based on the AFC, women will
be classified into four categories; AFC less than 8
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normal responders), AFC 11-15 (predicted normal
responders) or AFC above 15 (predicted hyperrespon-
ders). RCT 1 will contain 300 women with an AFC
below 11; RCT 2 will contain 300 women with an AFC
of more than 15. A total of 25 academic and non-
academic centres in the Netherlands will participate. An
economic analysis is incorporated to assess the cost-
effectiveness of an ORT and subsequent individualised
FSH dosage in IVF or ICSI treatment. Inclusion was
started in May 2011. This study will be conducted in ac-
cordance with the principles of the Declaration of Hel-
sinki and in accordance with Good Clinical Practice.
The study protocol has been approved by the Institu-
tional Review Board (IRB) of the University Medical
Center Utrecht (MEC 10-273) and by the board of direc-
tors of all participating centres.
Sample size calculation
Based on the expected gain in pregnancy rate resulting
in live birth as reported in the study by Popovic-
Todorovic et al. [12], we expect an increase in pregnancy
rate over three IVF or ICSI cycles of 15% (from 25% to
40%) in the predicted poor responders (RCT 1). To
demonstrate that such a difference will occur, we need
to include 300 couples in RCT 1 (alpha-error of 0.05
and a power of 80%, two-sided test). If we expect a posi-
tive effect of dose adjustment in both the predicted poor
responders (RCT 1) and predicted hyperresponders
(RCT 2), the total sample size of 600 women, in both
RCTs, allows the detection of an increase in pregnancy
rate from 30% after conventional treatment to 41% in
the dose adjustment group (alpha-error of 0.05 and a
power of 80%, two-sided test). If the net effect of dose
adjustment on pregnancy rate is less than 11%, it is un-
likely that an ORT and dose adjustment is cost-effective.
The assumed 30% success rate in the conventional group
in the latter calculation is higher than the assumed 25%
success rate in the conventional group of solely RCT 1,
as RCT 1 only contains women with an expected poor
response. RCT 2 adds women with a predicted hyperre-
sponse, who are expected to have higher pregnancy
rates. For RCT 2 an increase in pregnancy rate from
35% to 42% over three cycles is expected. With 300 par-
ticipants the power to detect this difference is 24%.
In our Individual Patient Data meta-analysis on 2,300
patients in 13 studies, we found that 25% had and AFC
below 6, 18% had an AFC between 6 and 9, 33% had an
AFC between 10 and 15 and 24% had an AFC of more
than 15 [12].If we assume that 20% of the couples will
have a low or low-normal ovarian reserve, and are there-
fore eligible for the predicted poor responder trial, we
need to include a cohort of 1,500 women for ovarian re-
serve screening in order to achieve the necessarynumber of participants for the two trials. This will then
allow a sample size of just over 300 women for RCT 1.
A sample size calculation for the cost effectiveness ana-
lysis is not provided. It is generally accepted that this type
of sample size is not provided because the uncertainty of
the cost economy ratio is largely determined by the vari-
ation in the efficacy (the denominator of the ratio) and
can therefore not be performed at a realistic level.
Recruitment, consent and randomisation
Eligible women with an indication for a first IVF or ICSI
treatment cycle or a first IVF or ICSI treatment cycle
after birth of a child will receive oral and written infor-
mation from their attending physician. The investigator
will explain the study fully and in sufficient detail to
allow the women to make an informed decision whether
to participate or not. If a woman is willing to participate,
written informed consent will be obtained. Based on
AFC classification women will be entered into one of
the four AFC classes (see Figure 1). Participants, exclud-
ing the predicted normal responders, will be randomly
allocated to a standard or individualised FSH regime. All
predicted normal responders will receive the standard
dosage. Randomisation will be performed centrally by a
web-based randomisation program and will be stratified
by centre.
Study population
All subfertile women indicated for a first IVF or ICSI
cycle, who are aged < 44 years, have a regular menstrual
cycle and no major uterine or ovarian abnormalities at
TVS are considered to be eligible for participation.
Women with polycystic ovary syndrome (PCOS) and
(uncorrected) endocrine or metabolic abnormalities, as
well as women undergoing IVF after oocyte donation,
will not be included.
Study procedures
The AFC will be measured to assess ovarian reserve cap-
acity. The AFC will be performed in the early follicular
phase (cycle day 1–3) of the stimulation cycle by using a
standard TVS based measurement and count of all ovar-
ian follicles sized 2–10 mm in both ovaries, performed by
experienced physicians trained in applying this ultrasound
test. On the same day serum will be obtained for post hoc
analysis of endocrine ovarian reserve tests. Based on the
result of the AFC women will either receive a standard or
elevated FSH dosage (RCT 1) or a standard or reduced
FSH dosage (RCT 2). All predicted normal responders will
receive the standard dose regime. Recombinant or urinary
FSH will be used for ovarian stimulation. Stimulation with
the assigned FSH dose will be initiated on cycle day 2 or
3. Dose adjustments in the course of the stimulation cycle
are not allowed. A gonadotrophin-releasing hormone
Eligible Case
Informed Consent
Ultrasound AFC 2-10 mm
FSH 150 IU 
GnRhagonistor
FSH 450 IU 
AFC   16-40 foll
AFC   0-7 foll
AFC   8-10 foll
GnRhagonistor
GnRhagonistor
FSH 225 IU 
FSH 150 IU 
FSH 100 IU 
FSH 150 IU 
RCT 1
RCT 2
GnRhantagonist
FSH 150 IU 
GnRhagonistor
AFC   11-15 foll
GnRhantagonist
GnRhantagonist
GnRhantagonist
Figure 1 Study procedure.
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co-treatment protocol will be used for luteinizing hor-
mone (LH) peak suppression. The participating hospitals
will apply only one of the methods of LH suppression for
all participants included in the study (GnRH analogue
stratification). Final oocyte maturation will be achieved by
administration of human chorionic gonadotrophin (hCG)
when three or more follicles of 17 mm are present. Oocyte
retrieval will be carried out 34–36 hours after hCG ad-
ministration. Embryo transfer will be performed 3–5 days
after ovum pick- up. Luteal phase supplementation will
consist of 600 mg micronized progesterone in three separ-
ate dosages starting one day after oocyte retrieval and con-
tinued until 18 days after ovum pick-up. All participants
will undergo a maximum of three IVF or ICSI cycles dur-
ing a treatment period of maximally 18 months.
Experimental group
All women in the experimental group will receive an
individualised FSH dose based on their AFC. If women
in RCT 1 are randomised for dose adjustment they will
use 450 IU FSH/day if the AFC is below 8 and 225 IU
FSH/day if the AFC is 8-10. Women in RCT 2 will re-
ceive 100 IU FSH/day if they are randomised for dose
adjustment. Participants will be subjected to the assigned
dosage in the subsequent cycles. In RCT 1, dose adjust-
ments are not allowed in a subsequent cycle. For women
in RCT 2, dose adjustment in the second or third cycle
is allowed, and can consist of a step of 25 IU FSH/day, if
there is a poor response or hyperresponse (poor re-
sponse is defined as the retrieval of less than five oocytes
or the cancellation of a stimulation cycle because less
than two follicles above 12 mm in diameter are observedon ultrasound; hyperresponse is defined as the retrieval
of more than 15 oocytes or cancellation of a stimulation
cycle because more than 20 follicles over 12 mm in
diameter are growing and estradiol levels exceed 11.700
pmol/L (= 3187,08 ng/L) or if more than 30 follicles over
12 mm are growing).
Control group
All women in the control group will receive a standard
FSH dose of 150 IU/day, independent of the AFC classi-
fication. They will be subjected to the assigned dosage in
the subsequent cycles. However, based on the response
in preceding cycles, a dose adjustment in the second and
third cycle is allowed, but cannot exceed a step of 50 IU
FSH/day, if there has been a poor response or hyperre-
sponse (as defined above).
Withdrawal of individual patients
Subjects can abandon the study at any time for any rea-
son if they wish to do so without any consequences. The
investigator can decide to withdraw a subject from the
study for urgent medical reasons.
Outcome measures
The primary study outcome is the cumulative pregnancy
rate achieved within 18 months after randomisation
resulting in live birth. Pregnancies can be obtained in
treatment cycles with fresh embryos as well as in subse-
quent cryo/thaw cycles. Spontaneous pregnancies be-
tween treatment cycles will also be taken into account.
The data will be integrated in a cost-effectiveness
analysis. Differentiation will be made between direct
medical costs (all health care sector costs), direct non-
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are affected by health status or health care) and indirect
costs of the fertility treatment (costs of sick leave due to
fertility treatment). For medical costs, the process of care
will be divided into two cost stages (cost of fertility treat-
ment, cost of pregnancy), which can reoccur if women
have repeat treatment cycles within the study period.
These costs will be computed from the period of inclu-
sion to the end of follow-up (18 months).
Direct non-medical and indirect costs may be gener-
ated if women are absent from paid work, either for vis-
iting the fertility clinic during IVF or ICSI treatment or
due to sick leave associated with physical or psycho-
logical side-effects of this treatment. The Health and
Labour Questionnaire [13] will be used to document ab-
sence from paid work.
Fertility health care utilisation consists of hospital vis-
its, TVS, gonadotrophins, endocrine laboratory tests,
ovum pick-up, IVF or ICSI laboratory work and hospital
care. Volumes of health care resource use will be mea-
sured alongside the clinical study in several participating
centres by using a checklist.
Secondary study outcomes consist of the number of
retrieved oocytes, the occurrence of poor response or
hyperresponse, OHSS grade 2/3, the rate of cycle
cancellation, the number of multiple pregnancies and
total IU of FSH used per stimulation cycle.
Statistical analysis
SPSS and Excel will be used to perform the statistical
analysis. A probability (p) of less than 0.05 will be con-
sidered to be significant. Data will be presented for all
arms of the study group. Data will be expressed as
means ± standard deviation and proportions or rates.
The analysis will be by intention to treat.
Descriptive analysis will be used to describe the primary
and secondary outcome variables and to compare these
outcome variables among the treatment arms of the two
RCTs. Comparisons between the two arms of the rando-
mised group will be done by applying Chi/square testing
to crude rates of cumulative implantation and ongoing
pregnancy and by using life table analysis to account for
the factor of time to implantation or pregnancy. The rela-
tive contribution of predictive factors of success in any of
the treatment arms, such as female age and duration of
subfertility will be assessed by univariate and multivariate
logistic regression and Cox regression.
Economic analysis
From a societal perspective, we will perform an eco-
nomic analysis alongside the cohort study and clinical
trials. The data on cancellation rates, FSH consumption
and pregnancy rate from the cohort study (900 couples)
and the two RCTs (300 patients per study) will beintegrated in a cost-effectiveness analysis. We will build
on previous work that we have done for CVZ (College
Voor Zorgverzekeringen; College of Health Insurances).
In the analysis, we will assess the cost-effectiveness of
using an ORT for dose adjustments in poor responders
ór hyperresponders only and using an ORT for dose ad-
justment in both poor responders and hyperresponders,
as compared to current practice where no ORT is used
and standard FSH doses are given.
The study design will enable us to compare the costs
and effects of the following strategies:
I. IVF or ICSI without an ORT for three cycles with a
standard start dose (reference strategy)
II. ORT followed by IVF or ICSI with dose adjustment
in women with predicted hyperresponse and
predicted poor response
III. ORT followed by IVF or ICSI and dose reduction in
women with predicted hyperresponse only
IV. ORT followed by IVF or ICSI and dose adjustment
in women with predicted poor response only
The key question in the economic evaluation is to as-
sess whether the health and associated economic bene-
fits of individualised treatment of subfertile women in
terms of increased ongoing pregnancy rates and reduced
rates of hyperstimulation, outweigh the additional costs
of an ORT. The economic evaluation will be designed as
a cost-effectiveness analysis with the costs per pregnancy
resulting in live birth within 18 months as the primary
outcome measure. Cost-effectiveness of each strategy
will therefore be expressed as costs per live birth. The
incremental cost-effectiveness ratio (ICER) of each indi-
vidualised dose-adjustment strategy as compared to a
strategy with standard FSH dose will be estimated as the
ratio between difference in costs between strategies and
the difference in pregnancy rates, and reflects the extra
costs required to obtain one additional live birth. If in
the predicted poor response group individualised FSH
treatment following an ORT increases the live birth rate
without affecting OHSS rates, individualised treatment is
the dominant strategy. If in the predicted hyperresponse
group individualised FSH treatment following an ORT
reduces the rate of OHSS, without affecting live birth
rates, individualised treatment is the dominant strategy.
Discussion
The number of patients starting IVF or ICSI treatment
in the Netherlands annually is approximately 7,000 and
they undergo 16,000 IVF or ICSI cycles a year [14].
Women with a poor response or hyperresponse com-
prise 30- 55.8% of the population [11,15]. Bouwman
et al. [1] showed that hormonal stimulation is the most
expensive part of IVF and ICSI treatment.
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despite intensive and costly efforts to increase awareness
of the unavoidable ovarian failure associated with
advanced age. In the Netherlands, the age at which a
woman delivers her first child has increased from 25.5
years (1980) to 29.4 years (2011) making Dutch women
amongst the oldest mothers in the world [16]. As a re-
sult of this delayed child bearing, the most frequent indi-
cation for assisted reproductive techniques such as IVF
and ICSI is now unexplained subfertility in couples with
increased female age, in which diminished ovarian re-
serve is usually the cause. As a consequence, the poten-
tial value of an ORT is increasing.
A recently published Markov decision-analytic model
showed that individualisation of the FSH dose according
to ovarian reserve is likely to be cost-effective in women
who are eligible for IVF or ICSI treatment [17]. The use
of an ORT followed by individualised FSH regimens can
have a large impact on current IVF practice. The advan-
tages may include improvement of quality of life for the
patient, reduction of harm associated with conventional
IVF, increased effectiveness and reduction of costs.
The results of this study will be integrated into a deci-
sion model that compares cost-effectiveness of the three
dose-adjustment strategies to the standard FSH dose
strategy. The costs and the live birth rates of these strat-
egies will be assessed. The study outcomes will provide
scientific foundation for national and international
guidelines.
Abbreviations
AFC: Antral follicle count; AMH: Anti-Müllerian hormone; COH: Controlled
ovarian hyperstimulation; FSH: Follicle stimulating hormone;
GnRH: Gonadotrophin- releasing hormone; hCG: Human chorionic
gonadotrophin; ICER: Incremental cost-effectiveness ratio;
ICSI: Intracytoplasmic sperm injection; IVF: In vitro fertilisation; LH: Luteinizing
hormone; OHSS: Ovarian hyperStimulation syndrome; ORT: Ovarian reserve
test; PCOS: Polycystic ovary syndrome; RCT: Randomised controlled trial;
TVS: Trans vaginal sonography.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TT is responsible for the overall logistical aspects of the trial and drafted the
manuscript. HT and FB have contributed to the development of the protocol
and study design. FB applied for a grant. FB and HT have overall
responsibility for the trial. ME is responsible for the sample size calculation
and will be involved in the statistical analysis. JL, CK, JB, GS, RG, KF, AH, AN,
WK, AM, EB, AvH, AS, AV, MH, JF, JS, JK, HV, CL, FH, FV and BM are
responsible for implementation of the study and inclusion of eligible
patients. All authors read and approved the final manuscript.
Acknowledgements
This trial is funded by ZonMw (Project Number 171102020), the Netherlands
Organisation for Health Research and Development.
Author details
1Department of Reproductive Medicine and Gynaecology, University Medical
Centre Utrecht, University of Utrecht, Utrecht, The Netherlands. 2Julius Centre
for Health Sciences and Primary care, University Medical Centre Utrecht,
Utrecht, The Netherlands. 3Department of Obstetrics and Gynaecology,Division of Reproductive Medicine, Erasmus Medical Centre, Rotterdam, The
Netherlands. 4Department of Obstetrics and Gynaecology, Maxima Medical
Centre, Veldhoven, The Netherlands. 5Department of Obstetrics and
Gynaecology, Jeroen Bosch Hospital, Den Bosch, The Netherlands.
6Department of Obstetrics and Gynaecology, Gelre Hospital, Apeldoorn, The
Netherlands. 7Department of Obstetrics and Gynaecology, Maastricht
University Medical Centre, University of Maastricht, Maastricht, The
Netherlands. 8Department of Obstetrics and Gynaecology, University Medical
Centre St Radboud, Nijmegen, The Netherlands. 9Department of Obstetrics
and Gynaecology, University Medical Centre Groningen, University of
Groningen, Groningen, The Netherlands. 10Department of Obstetrics and
Gynaecology, Rijnstate Hospital, Arnhem, The Netherlands. 11Department of
Obstetrics and Gynaecology, Isala Clinics, Zwolle, The Netherlands.
12Department of Obstetrics and Gynaecology, Diakonessen Hospital Utrecht,
Utrecht, The Netherlands. 13Department of Obstetrics and Gynaecology,
Meander Medical Centre, Amersfoort, The Netherlands. 14Department of
Obstetrics and Gynaecology, St Antonius Hospital, Nieuwegein, The
Netherlands. 15Department of Obstetrics and Gynaecology, Wilhelmina
Hospital, Assen, The Netherlands. 16Department of Obstetrics and
Gynaecology, Maasstad Hospital, Rotterdam, The Netherlands. 17Department
of Obstetrics and Gynaecology, St Fransiscus Hospital, Rotterdam, The
Netherlands. 18Department of Obstetrics and Gynaecology, Gemini Hospital,
Den Helder, The Netherlands. 19Department of Obstetrics and Gynaecology,
St Elisabeth Hospital, Tilburg, The Netherlands. 20Department of Obstetrics
and Gynaecology, St Lucas Andreas Hospital, Amsterdam, The Netherlands.
21Department of Obstetrics and Gynaecology, Onze Lieve Vrouwe Hospital,
Amsterdam, The Netherlands. 22Department of Obstetrics and Gynaecology,
VU University Medical Centre, Amsterdam, The Netherlands. 23Department of
Obstetrics and Gynaecology, Leids University Medical Centre, University of
Leiden, Leiden, The Netherlands. 24Department of Obstetrics and
Gynaecology, Academic Medical Centre, University of Amsterdam,
Amsterdam, The Netherlands.
Received: 1 August 2012 Accepted: 3 September 2012
Published: 18 September 2012
References
1. Bouwmans CA, Lintsen BM, Eijkemans MJ, Habbema JD, Braat DD, Hakkaart
L: A detailed cost analysis of in vitro fertilization and intracytoplasmic
sperm injection treatment. Fertil Steril 2008, 89:331–341.
2. de Boer EJ, den Tonkelaar I, te Velde ER, Burger CW, Klip H, van Leeuwen FE,
OMEGA- project Group: A low number of retrieved oocytes at in vitro
fertilization treatment is predictive of early menopause. Fertil Steril 2002,
77:978–985.
3. de Boer EJ, de Tonkelaar I, te Velde ER, Burger CW, van Leeuwen FE,
OMEGA- project Group: Increased risk of early menopausal transition and
natural menopause after poor response at First IVF treatment. Hum
Reprod 2003, 18:1544–1552.
4. van der Gaast MH, Eijkemans MJ, van der Net JB, de Boer EJ, Burger CW,
van Leeuwen FE, Fauser BCJM, Macklon NS: Optimum number of oocytes
for a successful first IVF treatment cycle. Reprod Biomed Online 2006,
13:476–480.
5. Delvigne A, Rozenberg S: Epidemiology and prevention of ovarian
hyperstimulation syndrome (OHSS): a review. Human Reprod Update 2002,
8:559–577.
6. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB: A systematic
review of tests predicting ovarian reserve and IVF outcome. Human
Reprod Update 2006, 12:685–718.
7. Broer SL, Mol BW, Hendriks D, Broekmans FJ: The role of antimullerian
hormone in prediction of outcome after IVF: comparison with the antral
follicle count. Fertil Steril 2009, 91:705–714.
8. Bancsi LF, Broekmans FJ, Mol BW, Habbema JD, te Velde ER: Performance
of basal follicle-stimulating hormone in the prediction of poor ovarian
response and failure to become pregnant after in vitro fertilization: a
meta-analysis. Fertil Steril 2003, 79:1091–1100.
9. Hendriks DJ, Mol BW, Bancsi LF, te Velde ER, Broekmans FJ: The clomiphene
citrate challenge test for the prediction of poor ovarian response and
nonpregnancy in patients undergoing in vitro fertilization: a systematic
review. Fertil Steril 2006, 86:807–818.
10. Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ: Ultrasonography
as a tool for the prediction of outcome in IVF patients: a comparative
van Tilborg et al. BMC Women's Health 2012, 12:29 Page 7 of 7
http://www.biomedcentral.com/1472-6874/12/29meta-analysis of ovarian volume and antral follicle count. Fertil Steril
2007, 87:764–775.
11. Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsboll S, Nielsen IK,
Andersen AN: A prospective randomised clinical trial comparing an
individual dose of recombinant FSH based on predictive factors versus a
“standard” dose of 150 IU/day in “standard” patients undergoing IVF/ICSI
treatment. Hum Reprod 2003, 18:2275–2282.
12. Broer SL: Assessment of current and future ovarian reserve status, PhD thesis.:
Utrecht University, Department of Reproductive Medicine; 2011.
13. van Roijen Hakkaart L, Essink-Bot ML, Koopmanschap MA: Labor and health
status in economic evaluation of health care. The Health and Labor
Questionnaire. Int J Technol Assess Health Care 1996, 12:405–415.
14. Smeenk J, Kremer J: NVOG landelijke IVF-cijfers 1996-2010. http://www.nvog.
nl//Sites/Files/0000002344_IVF%20cijfers%202010.pdf.
15. Popovic-Todorovic B, Loft A, Ziebe S, Andersen AN: Impact of recombinant
FSH dose adjustments on ovarian response in the second treatment
cycle with IVF or ICSI in “ standard” patients treated with 150 IU/day
during the first cycle. Acta Obstet Gynecol Scand 2004, 83:842–849.
16. Statistics Netherlands: http://www.cbs.nl/nl-NL/menu/informatie/onderwijs/
actueel/maatschappijleer/archief/2011/2011-3424-wm1.htm.
17. Moolenaar LM, Broekmans FJM, van Disseldorp J, Fauser BCJM, Eijkemans
MJC, Hompes PGA, van der Veen F, Mol BWJ: Cost effectiveness of ovarian
reserve testing in in vitro fertilization: a Markov decision-analytic model.
Fertil Steril 2011, 96:889–894.
doi:10.1186/1472-6874-12-29
Cite this article as: van Tilborg et al.: The OPTIMIST study: optimisation
of cost effectiveness through individualised FSH stimulation dosages for
IVF treatment. A randomised controlled trial. BMC Women's Health 2012
12:29.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
